Role of cystatins in tumor neovascularization

Future Oncology

Volumn 1, Issue 5, 2005, Pages 661-672

  Keppler, Daniel ^a   Sierra, Felipe ^b  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

angiogenesis; cathepsins; cystatins; fetuins; histidine rich glycoprotein; kininogens; neovascularization; protease inhibitors; tumor invasion

Indexed keywords

CYSTATIN;

HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; VASCULARIZATION;

CYSTATINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33845334582     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.5.661     Document Type: Review

References (113)

1. Anastasi A, Brown MA, Kembhavi AA et al.: Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem. J. 211, 129-138 (1983)
2. Turk V, Bode W: The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 285, 213-219 (1991
3. Bromme D, Kaleta J: Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. 8(18), 1639-1658 (2002
4. Rawlings ND, Barrett AJ: Evolution of proteins of the cystatin superfamily. J. Mol. Evol. 30, 60-71 (1990
5. Keppler D: Towards novel anticancer strategies based on cystatin function. Cancer Lett. In Press (E-Pub ahead, May 10, 2005
6. Bode W, Engh R, Musil D et al.: The 2.0 A x-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J. 7, 2593-2599 (1988
7. Turk B, Dolenc I, Turk V, Bieth JG: Kinetics of the pH-induced inactivation of human cathepsin L. Biochemistry 32, 375, (1993
8. Turk B, Dolenc I, Zerovnik E, Turk D, Gubensek F, Turk V: Human cathepsin B is a metastable enzyme stabilized by specific ionic interactions associated with the active site. Biochemistry 33, 14800-14806 (1994
9. Turk B, Turk D, Salvesen GS: Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8(18), 1623-1637 (2002
10. Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D: Exocytosis of active cathepsin B: enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. 264, 100-109 (1999
11. Dehrmann FM, Coetzer TH, Pike RN, Dennison C: Mature cathepsin L is substantially active in the ionic milieu of the extracellular medium. Arch. Biochem. Biophys. 324, 93-98 (1995
12. Sloane BF, Rozhin J, Johnson K, Taylor H, Crissman JD, Honn KV: Cathepsin B: association with plasma membrane in metastatic tumors. Proc. Natl Acad. Sci. USA 83, 2483-2487 (1986
13. Guinec N, Dalet-Fumeron V, Pagano M: Quantitative study of the binding of cysteine proteinases to basement membranes. FEBS Lett. 308, 305-308 (1992
14. Selzer PM, Pingel S, Hsieh I et al.: Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc. Natl Acad. Sci. USA 96(20), 11015-11022 (1999
15. Caffrey CR, Scory S, Steverding D: Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets 1(2), 155-162 (2000
16. Authie E, Boulange A, Muteti D, Lalmanach G, Gauthier F, Musoke AJ: Immunisation of cattle with cysteine proteinases of Trypanosoma congolense: targeting the disease rather than the parasite. Int. J. Parasitol. 31(13), 1429-1433 (2001
17. Cornwall GA, Cameron A, Lindberg I, Hardy DM, Cormier N, Hsia N: The cystatin-related epididymal spermatogenic protein inhibits the serine protease prohormone convertase 2. Endocrinology 144(3), 901-908 (2003
18. Normant E, Martres MP, Schwartz JC, Gros C: Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor. Proc. Natl Acad. Sci. USA 92(26), 12225-12229 (1995
19. Aagaard A, Listwan P, Cowieson N et al.: An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. Structure 13(2), 309-317 (2005
20. Yamamoto K, Sinohara H: Isolation and characterization of mouse countertrypin, a new trypsin inhibitor belonging to the mammalian fetuin family. J. Biol. Chem. 268(24), 17750-17753 (1993
21. Yoshida K, Suzuki Y, Yamamoto K, Sinohara H: Cystatin-like domain of mouse countertrypin, a member of mammalian fetuin family, is responsible for the inhibition of trypsin. Evidence from sitedirected mutagenesis. Biochem. Mol. Biol. Int. 39, 1023-1028 (1996
22. Ray S, Lukyanov P, Ochieng J: Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities. Biochim. Biophys. Acta 1652(2), 91-102 (2003
23. Abrahamson M, Alvarez-Fernandez M, Nathanson CM: Cystatins. Biochem. Soc. Symp. (70), 179-199 (2003
24. Shi GP, Sukhova GK, Kuzuya M et al.: Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92(5), 493-500 (2003
25. Knight G: Active-site titration of peptidases. Methods Enzymol 248, 85-104 (1995
26. Joyce JA, Baruch A, Chehade K et al.: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5(5), 443-453 (2004
27. Amamoto T, Okazaki T, Komurasaki T et al.: Immunopharmacologic profiles of a thiol protease inhibitor, L-trans-dicyclohexyl epoxysuccinate. Jpn. J. Pharmacol. 34(3), 335-342 (1984
28. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl. 16), 15-18 (2002
29. Asahara T, Masuda H, Takahashi T et al.: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85(3), 221-228 (1999
30. Urbich C, Heeschen C, Aicher A et al.: Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nature Med. 11(2), 206-213 (2005
31. St Croix B, Rago C, Velculescu V et al.: Genes expressed in human tumor endothelium [see comments]. Science 289(5482), 1197-1202 (2000
32. Machein MR, Renninger S, de Lima-Hahn E, Plate KH: Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 13(4), 582-597 (2003
33. Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA, Sloane BF: Tumor progression and angiogenesis: cathepsin B & Co. Biochem. Cell Biol. 74(6), 799-810 (1996
34. Mikkelsen T, Yan PS, Ho KL et al.: Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J. Neurosurg. 83, 285-290 (1995
35. Rempel SA, Rosenblum ML, Mikkelsen T et al.: Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54, 6027-6031 (1994
36. Yanamandra N, Gumidyala KV, Waldron KGet al.: Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23(12), 2224-2230 (2004
37. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23(52), 8486-8496 (2004
38. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267(36), 26031-26037 (1992
39. Konduri SD, Yanamandra N, Siddique K et al.: Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21(57), 8705-8712 (2002
40. Taupin P, Ray J, Fischer WH et al.: FGF-2- responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine co-factor. Neurone 28(2), 385-397 (2000
41. Sokol JP, Schiemann WP: Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol. Cancer Res. 2(3), 183-195 (2004
42. Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, Vray B: Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. Eur. J. Biochem. 266(3), 1111-1117 (1999
43. Schierack P, Lucius R, Sonnenburg B, Schilling K, Hartmann S: Parasite-specific immunomodulatory functions of filarial cystatin. Infect. Immun. 71(5), 2422-2429 (2003
44. Kato T, Ito T, Imatani T, Minaguchi K, Saitoh E, Okuda K: Cystatin SA, a cysteine proteinase inhibitor, induces interferongamma expression in CD4-positive T-cells. Biol. Chem. 385(5), 419-422 (2004
45. Pedersen KO: Size relationship among similar proteins; association and dissociation reactions of protein units. Cold Spring Harbor Symposium on Quantitative Biolology 14, 140-152 (1950
46. Kellermann J, Haupt H, Auerswald EA, Muller-Ester W: The arrangement of disulfide loops in human alpha 2-HS glycoprotein. Similarity to the disulfide bridge structures of cystatins and kininogens. J. Biol. Chem. 264, 14121-14128 (1989
47. Olivier E, Soury E, Ruminy P et al.: Fetuin-B, a second member of the fetuin family in mammals. Biochem. J. 350(Pt 2), 589-597 (2000
48. Jones AL, Hulett MD, Parish CR: Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol. Cell Biol. 83(2), 106-118 (2005
49. Rizzu P, Baldini A: Three members of the human cystatin gene superfamily, AHSG, HRG, and KNG, map within one megabase of genomic DNA at 3q27. Cytogenet. Cell Genet. 70, 26-28 (1995
50. Hsu SJ, Nagase H, Balmain A: Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome 47(5), 931-946 (2004
51. Muller-Esterl W, Fritz H, Kellermann J, Lottspeich F, Machleidt W, Turk V: Genealogy of mammalian cysteine proteinase inhibitors. Common evolutionary origin of stefins, cystatins and kininogens. FEBS Lett. 191, 221-226 (1985
52. Elzanowski A, Barker WC, Hunt LT, Seibel- Ross E: Cystatin domains in alpha-2-HSglycoprotein and fetuin. FEBS Lett. 227, 167-170 (1988
53. Liu Q, Yu L, Gao J et al.: Cloning, tissue expression pattern and genomic organization of latexin, a human homologue of rat carboxypeptidase A inhibitor. Mol. Biol. Rep. 27(4), 241-246 (2000
54. Dickson IR, Poole AR, Veis A: Localisation of plasma alpha2HS glycoprotein in mineralising human bone. Nature 256(5516), 430-432 (1975
55. Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ: Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 262(5565), 226-227 (1976
56. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J.Biol. Chem. 271, 20789-20796 (1996
57. Schinke T, Koide T, Jahnen-Dechent W: Human histidine-rich glycoprotein expressed in SF9 insect cells inhibits apatite formation. FEBS Lett. 412, 559-562 (1997
58. Heiss A, DuChesne A, Denecke B et al.: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J. Biol. Chem. 278(15), 13333-13341 (2003
59. Jahnen-Dechent W, Schinke T, Trindl A et al.: Cloning and targeted deletion of the mouse fetuin gene. J. Biol. Chem. 272, 31496-31503 (1997
60. Szweras M, Liu D, Partridge EA et al.: Alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J. Biol. Chem. 277(22), 19991-19997 (2002
61. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW: Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta Type II receptor mimic and cytokine antagonist. J. Biol. Chem. 271, 12755-12761 (1996
62. Swallow CJ, Partridge EA, Macmillan JC et al.: alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res. 64(18), 6402-6409 (2004
63. Leite-Browning ML, McCawley LJ, Jahnen- Dechent W et al.: Alpha 2-HS glycoprotein (fetuin-A) modulates murine skin tumorigenesis. Int. J. Oncol. 25(2), 319-324 (2004
64. Kundranda MN, Henderson M, Carter KJ et al.: The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms. Cancer Res. 65(2), 499-506 (2005
65. Cayatte AJ, Kumbla L, Subbiah MT: Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. J. Biol. Chem. 265, 5883-5888 (1990
66. Rohrlich ST, Rifkin DB: Isolation of the major serine protease inhibitor from the 5-day serum-free conditioned medium of human embryonic lung cells and demonstration that it is fetuin. J. Cell. Physiol. 109(1), 1-15 (1981
67. Lewis JG, Andre CM: Enhancement of human monocyte phagocytic function by alpha 2HS glycoprotein. Immunology 42(3), 481-487 (1981
68. Wajih N, Borras T, Xue W, Hutson SM, Wallin R: Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells: evidence for an uptake mechanism for serum fetuin. J. Biol. Chem. 279(41), 43052-43060 (2004
69. Kundranda MN, Ray S, Saria M et al.: Annexins expressed on the cell surface serve as receptors for adhesion to immobilized fetuin-A. Biochim. Biophys. Acta 1693(2), 211-123 (2004
70. Ochieng J, Green B: The interactions of alpha 2HS glycoprotein with metalloproteinases. Biochem. Mol. Biol. Int. 40, 13-20 (1996
71. Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y: Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur. J. Biochem. 243, 753-761 (1997
72. Nagase H, Mao JH, Balmain A: A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc. Natl Acad. Sci. USA 96(26), 15032-15037 (1999
73. Hajjar DP, Boyd DB, Harpel PC, Nachman RL: Histidine-rich glycoprotein inhibits the antiproliferative effect of heparin on smooth muscle cells. J. Exp. Med. 165(3), 908-913 (1987
74. Brown KJ, Parish CR: Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 33(46), 13918-13927 (1994
75. Borza DB, Morgan WT: Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein. J. Biol. Chem. 272(9), 5718-5726 (1997
76. Jones AL, Hulett MD, Altin JG, Hogg P, Parish CR: Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J. Biol. Chem. 279(37), 78267-38276 (2004
77. Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL, Silverstein RL: Histidinerich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J. Clin. Invest. 107(1), 45-52 (2001
78. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP: CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138(3), 707-717 (1997
79. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature Med. 6(1), 41-48 (2000
80. Juarez JC, Guan X, Shipulina NV et al.: Histidine-proline-rich glycoprotein has potent anti-angiogenic activity mediated through the histidine-proline-rich domain. Cancer Res. 62(18), 5344-5350 (2002
81. Guan X, Juarez JC, Qi X et al.: Histidineproline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb. Haemost. 92(2), 403-412 (2004
82. Olsson AK, Larsson H, Dixelius J et al.: A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res. 64(2), 599-605 (2004
83. Zhang JC, Donate F, Qi X et al.: The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc. Natl Acad. Sci. USA 99(19), 12224-12229 (2002
84. Donate F, Juarez JC, Guan X et al.: Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res. 64(16), 5812-5817 (2004
85. Borza DB, Tatum FM, Morgan WT: Domain structure and conformation of histidine-proline-rich glycoprotein. Biochemistry 35, 1925-1934 (1996
86. Salvesen G, Parkes C, Abrahamson M, Grubb A, Barrett AJ: Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J. 234, 429-434 (1986
87. Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakanishi S: Structural organization of the human kininogen gene and a model for its evolution. J. Biol. Chem. 260, 8610-8617 (1985
88. Guo YL, Colman RW: Two faces of highmolecular- weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J. Thromb. Haemost. 3(4), 670-676 (2005
89. Herwald H, Hasan AA, Godovac- Zimmermann J, Schmaier AH, Muller- Esterl W: Identification of an endothelial cell binding site on kininogen domain D3. J.Biol. Chem. 270, 14634-14642 (1995
90. Hayashi I, Amano H, Yoshida S et al.: Suppressed angiogenesis in kininogendeficiencies. Lab. Invest. 82(7), 871-880 (2002
91. Colman RW, Pixley RA, Sainz IM et al.: Inhibition of angiogenesis by antibody blocking the action of proangiogenic highmolecular- weight kininogen. J. Thromb. Haemost. 1(1), 164-170 (2003
92. Song JS, Sainz IM, Cosenza SC et al.: Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 104(7), 2065-2072 (2004
93. Emanueli C, Minasi A, Zacheo A et al.: Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischaemia. Circulation 103(1), 125-132 (2001
94. Emanueli C, Madeddu P: Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol. Sci. 22(9), 478-484 (2001
95. Regoli D, Jukic D, Gobeil F, Rhaleb NE: Receptors for bradykinin and related kinins: a critical analysis. Can. J. Physiol. Pharmacol. 71(8), 556-567 (1993
96. Ikeda Y, Hayashi I, Kamoshita E et al.: Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res. 64(15), 5178-5185 (2004
97. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M: The bradykinin/B1 receptor promotes angiogenesis by upregulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 15(8), 1487-1489 (2001
98. Seegers HC, Hood VC, Kidd BL, Cruwys SC, Walsh DA: Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J. Pharmacol. Exp. Ther. 306(1), 8-12 (2003
99. Thuringer D, Maulon L, Frelin C: Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J. Biol. Chem. 277(3), 2028-2032 (2002
100. Browder T, Folkman J, Pirie-Shepherd S: The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275(3), 1521-1524 (2000
101. Zhang JC, Claffey K, Sakthivel R et al.: Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. 14(15), 2589-2600 (2000
102. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA: Domain 5 of high molecular weight kininogen (kininostatin) downregulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95(2), 543-550 (2000
103. Weisel JW, Nagaswami C, Woodhead JL et al.: The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J. Biol. Chem. 269, 10100-10106 (1994
104. Joseph K, Tholanikunnel BG, Ghebrehiwet B, Kaplan AP: Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb. Haemost. 91(1), 61-70 (2004
105. Guo YL, Wang S, Cao DJ, Colman RW: Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J. Cell. Biochem. 89(3), 622-632 (2003
106. Guo YL, Wang S, Colman RW: Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21(9), 1427-1433 (2001
107. Hasan AA, Cines DB, Zhang J, Schmaier AH: The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J. Biol. Chem. 269, 31822-31830 (1994
108. Nakazawa Y, Joseph K, Kaplan AP: Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5. Int. Immunopharmacol. 2(13-14), 1875-1885 (2002
109. Espinola RG, Uknis A, Sainz IM et al.: A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am. J. Pathol. 165(3), 969-976 (2004
110. Muraoka-Cook RS, Dumont N, Arteaga CL: Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 11(2 Pt 2), S937-S943 (2005
111. Somoza J.R., Jiang F., Tong L., Kang C.H., Cho J.M., Kim S.H., J. Mol. Biol., 234, 390-404.
112. Somoza JR, Jiang F, Tong L, Kang CH, Cho JM, Kim SH: Two crystal structures of a potently sweet protein. Natural monellin at 2.75 A resolution and single-chain monellin at 1.7 A resolution. J. Mol. Biol. 234, 390-404 (1993)
113. Merops peptidase database merops.sanger.ac.uk (Accessed September 2005)